Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
RGREGENXBIO Inc. logo

REGENXBIO Inc. (RGNX)

NASDAQ Global Select · Currency in USD
$6.68 ▼ -0.49 (-6.83%)
At close: Oct 23, 4:00 PM ET. Market closed.
$6.73 ▲ +0.05 (+0.75%)
After hours: Oct 23, 7:33 PM ET

Summary

Previous Close
$7.17
Open
$7.03
Day's Range
$6.62 – $7.08
52 Week Range
$5.46 – $16.19
Volume
1,441,445
Avg. Volume
1,805,971
Market Cap
$440.97M
Beta (5Y Monthly)
0.93
PE Ratio (TTM)
--
EPS (TTM)
-$3.72
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$20.00

Profile: REGENXBIO Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
371
CEO
Curran Simpson

REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$1.24 · Revenue est. $14.88M
DateEst.Actual
Aug 6, 2026$0.08$0.43Beat
May 14, 2026-$1.36-$1.72Miss
Mar 5, 2026-$1.01-$1.30Miss
Nov 6, 2025-$1.38-$1.20Beat
Aug 7, 2025-$1.13-$1.38Miss
May 12, 2025$0.41$0.12Miss

Analyst view

Consensus price target
$20.00 ▲ +199.4%
Range $12.00 – $29.00
Rating: Buy
Buy 65% · Hold 30% · Sell 5%

Get free alerts on RGNX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.